Dr. Anampa Mesias is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1695 Eastchester Rd
2nd floor
Bronx, NY 10461Phone+1 718-405-8505Fax+1 718-405-8433
Summary
- I am a breast medical oncologist with a strong interest in new therapeutic approaches and immune therapies for breast cancer. My goal is to help patients who are affected with breast diseases and provide the state of art treatment for them. In addition to my clinical practice, I participate in clinical/translational research, and I am also an educator for future oncology physicians.
Education & Training
Albert Einstein college of MedicineMS, Clinical research, MS with Distintion, 2016 - 2018
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2011 - 2014- Rochester General HospitalResidency, Internal Medicine, 2008 - 2011
Cayetano Heredia UniversityClass of 2006
Certifications & Licensure
NY State Medical License 2014 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pilot Study Assessing the Effect of Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in Patients With ER+/HER2- Metastatic Breast Cancer Start of enrollment: 2019 Jan 08
Roles: Principal Investigator
Publications & Presentations
PubMed
- Racial disparities in treatment and outcomes between Hispanic and non-Hispanic black women with triple-negative breast cancer.Jesus D Anampa, Alvaro Alvarez Soto, Ana M Bernal, Ana Acuna-Villaorduna
Breast Cancer Research and Treatment. 2024-11-26 - Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.Jesus D Anampa, Daniel L Flynn, Cynthia Leary, Sun Oh, Xiaonan Xue
Clinical Cancer Research. 2024-11-12 - Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast.Jesus D Anampa, Shuwen Lin, Samilia Obeng-Gyasi, Xiaonan Xue
Cancer Epidemiology, Biomarkers & Prevention. 2024-10-24
Press Mentions
By the Numbers: Monthly Treatment Cost Not Tied to Survival in Breast CancerSeptember 26th, 2024
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
